S. 142 · 118th Congress · Health

Preserve Access to Affordable Generics and Biosimilars Act

Died in the Senate7.3k words Introduced Jan 30, 2023 · Latest action Mar 1, 2023

How far it has goneStopped at 3 of 6 · Died in the Senate
  1. IntroducedJan 30, 2023 Done
  2. CommitteeReported Mar 1, 2023 Done
  3. Senate floorDied Jan 3, 2025 Stopped here
  4. House floorNot yet Not reached yet
  5. Chambers agreeNot yet Not reached yet
  6. PresidentNot yet Not reached yet

What it does

This bill authorizes the Federal Trade Commission (FTC) to initiate proceedings against parties to any agreement resolving or settling a patent infringement claim in connection with the sale of a drug or biological product. Such an agreement is presumed to have anticompetitive effects and is a violation of this bill if the filer of the generic drug or biosimilar application receives anything of value and agrees to limit or forego research, development, manufacturing, marketing, or sales of the generic drug or biosimilar.

An agreement is exempted if the only consideration granted to the generic manufacturer is (1) the right to market and secure final approval for its product prior to the expiration of any statutory exclusivity, (2) a payment for reasonable litigation expenses, or (3) a covenant not to sue on any claim that the generic drug or biosimilar infringes a patent. An agreement is also exempt if the agreement's pro-competitive benefits outweigh the anticompetitive effects.

When a generic or biosimilar drug manufacturer enters into an agreement with another drug manufacturer related to the manufacturing, marketing, or sale of a drug, the manufacturers must certify that the material they have given the FTC concerning the agreement contains the complete agreement and any agreements related to that main agreement, including descriptions of any oral agreements or representations.

The bill imposes penalties for violations of this bill, including the forfeiture of the 180-day marketing exclusivity period for a generic drug.

Congressional Research Service · summary of “Reported to Senate” version · Mar 1, 2023

Who lobbies on it

20 organizations · 144 filings · Q1 2023–Q4 2024

One square per quarter since introduction, oldest left. Filled = named it that quarter.

  1. Chamber of Commerce of the U.s.a. 8 of 8 quarters
    “H.R. 5475, Prohibiting Adversarial Patents Act of 2023 H.R. 8070, National Defense Authorization Act for Fiscal Year 2025 S. 79, Interagency Patent Coordination and Improvement Act of 2023 S. 142, Preserve Access to Affordable Generics and Biosimilars Act S. 150, Affordable Prescriptions for Patients Act of 2023…”

    Q4 2024 filing · $74.5M lobbying spend in 2024, all issues

  2. Pharmaceutical Research and Manufacturers of America 8 of 8 quarters
    “H.R. 1717: Interagency Patent Coordination and Improvement Act of 2023 H.R. 4370: PREVAIL Act - Provisions related to the PTAB H.R. 4692: Increasing Prescription Drug Competition Act - Patent-related policy issues H.R. 5429: Medication Affordability and Patent Integrity Act H.R. 5475: Prohibiting Adversarial Patents…”

    Q4 2024 filing · $31.0M lobbying spend in 2024, all issues

  3. America's Health Insurance Plans Inc (ahip) 8 of 8 quarters
    “H.R. 1613 - Drug Price Transparency in Medicaid Act of 2023 - Rep. Carter, Earl - spread-pricing by PBMs for Medicaid H.R. 2880 - Protecting Patients Against PBM Abuses Act - Rep. Carter, Earl - PBM transparency H.R. 4818 - Treat and Reduce Obesity Act - Rep. Wenstrup, Brad - weight loss coverage H.R. 5372 - Expanding…”

    Q4 2024 filing · $11.8M lobbying spend in 2024, all issues

17 more organizations, every filingPROUpgrade

Organizations that named S. 142 in a quarterly lobbying report. Covers organizations with a PAC on file; reports from organizations without one aren’t loaded yet. Spend is the organization’s total across all issues: reports don’t split spending by bill. Source: Senate lobbying disclosures (LD-2) from lda.gov; quotes are word for word from the “specific lobbying issues” field.

Actions

5 actions · newest first
  1. Mar 1, 2023Placed on Senate Legislative Calendar under General Orders. Calendar No. 20.
  2. Mar 1, 2023Committee on the Judiciary. Reported by Senator Durbin with an amendment in the nature of a substitute. Without written report.
  3. Feb 9, 2023Committee on the Judiciary. Ordered to be reported with an amendment in the nature of a substitute favorably.
  4. Jan 30, 2023Read twice and referred to the Committee on the Judiciary.
Show all 5 actionsShow fewer
  1. Jan 30, 2023Introduced in Senate